JNJ vs. ONC: Johnson & Johnson vs. BeOne Medicines Stock Comparison

Company Profile

Johnson & Johnson (JNJ) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JNJ is classified in Pharmaceuticals while ONC is classified in Biotechnology.

Johnson & Johnson (JNJ) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Johnson & Johnson (JNJ) at 20.02% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Johnson & Johnson (JNJ) at 16.20% and BeOne Medicines (ONC) at 13.86% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Johnson & Johnson (JNJ) at 25.74% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Johnson & Johnson (JNJ) at 6.05% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Johnson & Johnson (JNJ) reports EPS growth of 90.50%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JNJ.

Both Johnson & Johnson (JNJ) at 0.55 and BeOne Medicines (ONC) at 0.35 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

Dividend Metrics

Valuation

Johnson & Johnson (JNJ) at 41.92 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Johnson & Johnson (JNJ) at 6.69 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both Johnson & Johnson (JNJ) at 8.16 and BeOne Medicines (ONC) at 7.98 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics